Real-World Outcomes for Patients Treated With Immune Checkpoint Inhibitors in the Veterans Affairs System

Abstract

This study describes ICI outcomes across multiple tumor types in a real-world population at the VA. For most indications, real-world survival outcomes are observed to be lower than those reported in PCTs, but patients receiving ICIs still achieve longer survival relative to patients receiving standard of care.